Freeline is a biotechnology company that develops transformative gene therapies for systemic debilitating diseases.
Freeline has raised $26.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2022.
Freeline's investors include Wellington Management, Novo Holdings, Innovate UK, Cowen Healthcare Investments, Acorn Bioventures.
Freeline is headquartered in Stevenage, United Kingdom.
Freeline is a biotechnology company that develops transformative gene therapies for systemic debilitating diseases.
Freeline is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Freeline — Funding & Investors." VCBacked, March 10, 2022, https://www.vcbacked.co/company/freeline. Accessed November 12, 2026.
VCBacked. (2022). Freeline — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/freeline
{{cite web |title=Freeline — Funding & Investors |url=https://www.vcbacked.co/company/freeline |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Freeline? Request a listing update